Thank You Tucaman I felt good when I saw Raf's post showing that Vascepa TRx gain was greater than Generic Lovaza TRx gain But now see your post showing that the Generic Lovaza NRx gain is greater than the Vascepa NRx gain Bottom Line is that it appears that Vascepa is currently not making much, if any, headway against Generic Lovaza Is anyone graphing this over the last several years? It would be great to see some kind of historical comparison.
Market Data 
Markets
AI
